It is common that cancer patients have different molecular signatures even though they have similar clinical features, such as histology, due to the heterogeneity of tumors. To overcome this variability, we previously developed a new approach incorporating prior biological knowledge that identifies knowledge-driven genomic interactions associated with outcomes of interest. However, no systematic approach has been proposed to identify interaction models between pathways based on multi-omics data. Here we have proposed such a novel methodological framework, called metadimensional knowledge-driven genomic interactions (MKGIs). To test the utility of the proposed framework, we applied it to an ovarian cancer dataset including multi-omics profiles from The Cancer Genome Atlas to predict grade, stage, and survival outcome. We found that each knowledge-driven genomic interaction model, based on different genomic datasets, contains different sets of pathway features, which suggests that each genomic data type may contribute to outcomes in ovarian cancer via a different pathway. In addition, MKGI models significantly outperformed the single knowledge-driven genomic interaction model. From the MKGI models, many interactions between pathways associated with outcomes were found, including the mitogen-activated protein kinase (MAPK) signaling pathway and the gonadotropin-releasing hormone (GnRH) signaling pathway, which are known to play important roles in cancer pathogenesis. The beauty of incorporating biological knowledge into the model based on multi-omics data is the ability to improve diagnosis and prognosis and provide better interpretability. Thus, determining variability in molecular signatures based on these interactions between pathways may lead to better diagnostic/treatment strategies for better precision medicine.
INTRODUCTION
Precision medicine, an emerging approach to disease prevention and treatment strategies that takes into account patients' environmental and genomic variabilities, is moving toward a new era of medicine. 1 As a near-term goal of the Precision Medicine Initiative, there will be increased efforts in cancer genomics to better diagnose, prevent, and treat many cancers. 1 To improve the success of prevention and treatment for more cancers, a better understanding of the underlying genetic architectures that drive different cancers is needed. Since cancer is an extremely heterogeneous disease, variability in multiomics data, such as somatic mutation, copy number alteration (CNA), DNA methylation, miRNA, gene expression, and protein expression, should be captured simultaneously.
Large-scale collaborative initiatives such as The Cancer Genome Atlas (TCGA) and the International Cancer Genome Consortium have been generating multi-omics data, mostly using the latest sequencing technologies along with patients' clinical data, and are providing unprecedented opportunities to deepen our understanding of the complex mechanisms of cancer in order to move forward to the next phase of personalized medicine. 2, 3 Since different dimensional genomic datasets are regarded as partially independent from and partially complementary to one another, there has been an everincreasing demand for the development of data integration methodologies. 4, 5 Thus, many data integration approaches for combining multi-omics data have been proposed to improve predictions of cancer clinical outcomes. [6] [7] [8] [9] [10] [11] [12] [13] Furthermore, it is common that cancer patients have different molecular signatures even though they have similar clinical features, such as histology, due to the heterogeneity of tumors. 14 Therefore, new data integration approaches incorporating biological knowledge such as pathways were also developed to overcome the variability of diagnostic and prognostic predictors. [15] [16] [17] Previously, we proposed a new approach that identifies knowledgedriven genomic interactions. These are defined by combining information from biological knowledge databases and patient genomic profiles to develop models associated with outcomes of interest. 18 However, the previous approach was focused on gene expression data alone. As one of the metadimensional analysis approaches, a concatenation-based integration approach combines multiple datasets for each sample into one large input matrix before building a model. 4 One advantage of this approach is that it considers combinations of dimensional genomic data and any possible interactions that may exist between them. 4 For example, one might try to detect an underlying model consisting of a pathway altered from gene expression that interacts with another pathway altered from CNA or a somatic mutation to explain clinical outcomes. If these 2 pathways are not combined into 1 model, the true signal might be missed. This is of special interest in cancer, because it has been shown that pathways will often interact with one another rather than act singularly. 19, 20 For example, several pathways, including the MAPK pathway, can activate the P53 pathway, which then regulates the expression of P21, thereby controlling the cell cycle pathway. However, no systematic approach has been proposed to identify interaction models between pathways based on multi-omics data.
In this study, we propose a novel methodological framework that integrates multi-omics data and biological knowledge to determine metadimensional knowledge-driven genomic interactions (MKGIs) associated with cancer clinical outcomes. Through this study, we tried to answer the following questions: (1) Do knowledge-driven genomic interaction models using different multi-omics data contain similar sets of pathways or different sets of pathways? (2) Do MKGI models improve the ability to explain outcomes of interest as cross-talk between pathways altered by multi-omics data? To demonstrate its utility and answer these questions, we applied the proposed framework to an ovarian cancer dataset from TCGA and used pathway information representing biological knowledge. An integrated view of crosstalk between pathways using multi-omics data may improve our understanding of the complex mechanisms of ovarian cancer and reduce variability between patients.
MATERIALS AND METHODS

Data
Normalized and preprocessed multi-omics datasets, including CNA, DNA methylation, and gene expression data, in ovarian cancer were downloaded from TCGA data matrix (http://tcga-data.nci.nih.gov/ tcga/) and cBio Cancer Genomics Portal (http://www.cbioportal. org/public-portal/) ( Table 1) . Each genomic dataset was retrieved as a gene-based feature set to map the genomic features to pathways. To retrieve the significantly altered copy number regions across a set of cancer patients, a CNA dataset resulting from the Genomic Identification of Significant Targets in Cancer (GISTIC) method was obtained from the cBio Portal. 21 Thus, 1887 genes with log 2 copy number values were extracted from significantly altered CNA regions in ovarian cancer. The DNA methylation dataset, containing 9129 genes, was constructed by choosing elements that were the least correlated with gene expression when genes were mapped with multiple methylation probes. Gene-centric expression values were obtained by remapping the probes to the human genome 36.1. An Affymetrix CDF file and Affymetrix.aroma were used for this, resulting in 12 042 genes with expression values and none with missing values.
Three binary classification problems were formulated by using clinical information from ovarian cancer patients. Clinical outcomes of TCGA ovarian cancer datasets were classified as follows: (1) early stage (T1 or T2) or late stage (T3 or T4), (2) low grade (G1 or G2) or high grade (G3 or G4), and (3) short-term (<3 years) or longterm (3 years) survival (Table 2 ). Demographic characteristic per outcome is presented in Table 3 .
Numbers represent sample size unless otherwise noted. SD, standard deviation.
Transforming knowledge-driven datasets using Biofilter
Biofilter is a software tool used for high-throughput annotation and construction of biologically informed models in a single convenient interface. 22 This software also filters genomic data by accessing multiple publicly available bioinformatics data sources via a built-in database called the Library of Knowledge Integration (LOKI). Included in LOKI is information about the genomic coordinates of SNPs and genes and about biological networks such as pathways, which can be used to determine relationships between multi-omic features. Additional information regarding Biofilter can be found at http://ritchielab.psu.edu/software/. One possible use of Biofilter is to identify knowledge-driven genomic interaction models using machine-learning methods by incorporating relevant biological knowledge. For this study, we used the Kyoto Encyclopedia of Genes and Genomes from Biofilter as the biological knowledge to identify such interactions associated with clinical outcomes. In total, we used 281 Kyoto Encyclopedia of Genes and Genomes pathways available in LOKI for the analysis. A conceptual overview of the analysis pipeline, consisting of a transformation step and a modeling step, is illustrated in Figure 1 . In the transformation step, a single genomic dataset, such as a gene expression matrix, is transformed into pathway-based matrices that we call knowledge-driven datasets, as proposed previously. 18 To perform this, genes in the gene expression data were first mapped to pathways. For all genes/pathways, any genes found within a concomitant pathway were grouped together. Then, each pathway became a new matrix feature for each patient by summing up the gene expression values across genes belonging to each pathway. Lastly, since the values of pathway features may be biased toward the total number of gene members belonging to each pathway, the pathway feature value was divided by the total number of gene members in that pathway. A representation of the development of these knowledge-driven datasets is shown on the upper side of Figure 1 .
Following the transformation step, we used grammatical evolution neural network (GENN) 23 to generate knowledge-driven genomic interaction models associated with clinical outcomes of interest. We Numbers represent sample size unless otherwise noted. SD, standard deviation. Figure 1 . A conceptual illustration of the analysis pipeline. First, original genomic dataset, copy number alteration (CNA), methylation, gene expression, and protein expression are transformed to knowledge-driven dataset based on pathway knowledge. Second, transformed datasets from multi-omics data are used to identify multiple knowledge-driven genomic interactions associated with clinical outcomes. Last, multiple knowledge-driven genomic interaction models can be combined to determine integrated knowledge-driven genomic interactions associated with outcomes of interest (cancer image from 24 ).
then integrated multiple knowledge-driven genomic interaction models, which were generated from different genomic datasets, to develop MKGI models associated with cancer outcomes such as survival ( Figure 1 ).
Analysis Tool for Heritable and Environmental Network Associations
Analysis Tool for Heritable and Environmental Network Associations (ATHENA) was previously developed to build metadimensional models that examine the genetic etiology of complex diseases, including cancer, by simultaneously analyzing metadimensional genomic data. 10, 25 These include but are not limited to CNA, methylation, gene expression, and protein expression data. ATHENA provides the following key functions: (1) feature selection from independent variables, both categorical and continuous; (2) prediction of categorical and continuous outcomes by modeling single variable effects and/or interaction effects; and (3) annotation of candidate models for interpretation in translational bioinformatics ( Figure 2 ). 25 We have extended ATHENA to identify knowledge-driven genomic interactions based on multi-omics data that explain the multilayered architecture of complex traits by incorporating Biofilter.
Two subcomponents, transformation using Biofilter and modeling using an evolutionary algorithm-based machine learning technique, are at ATHENA's core (Figure 2 ). We used CNA data as genomic dimension, methylation data as epigenome dimension, and gene expression data as transcriptome dimension for the current task in order to determine the MKGI models of complex disease. Currently, ATHENA contains 3 different evolutionary algorithm-modeling methods: GENN, Grammatical Evolution Symbolic Regression, and Grammatical Evolution Bayesian Network. We used GENN as the modeling component for analysis. ATHENA is open source and available at http://ritchielab.psu.edu/software/.
Grammatical Evolution Neural Networks
A number of computational methods, such as multifactor dimensionality reduction, have been proposed to uncover interactions between genomic features. 26, 27 However, many of them exhaustively search every possible combination of such features to build interaction models, and when integrating metadimensional data, search space volume grows exponentially with the number of integrated genomic features. In an attempt to circumvent this, evolutionary algorithm-based stochastic methods such as GENN have been proposed and applied. 23, 28, 29 One such evolutionary search algorithm, Figure 2 . Overview of ATHENA. ATHENA contains transformation and modeling components. The transformation component incorporates Biofilter to transform gene-based input data into a knowledge-based matrix. Multi-omic data can be the input to develop knowledge-driven genomic interaction models associated with clinical outcomes and further determine MKGI models using an evolutionary algorithm modeling method, GENN, as a modeling component.
grammatical evolution, is a more flexible type of genetic programming because it uses adaptations of grammar rules to evolve functional solutions ( Figure 2 ). 23 GENN, which uses artificial neural networks, optimizes the input features, weight, and network structures simultaneously. The GENN algorithm and grammar rules were described in further detail in a previous study, 23 but a brief summary of the algorithm is as follows:
Step 1: The input data is divided into 5 equal parts for 5-fold crossvalidations; 4 parts are used for training data and 1 part is used for testing data.
Step 2: A random population of binary strings is generated under a population size constraint and is initialized to be artificial neural networks based on grammar rules. The user specifies a number of central processing units (CPUs) so that the population is divided into several demes (semi-isolated subpopulations) for parallelization.
Step 3: The training data are used to evaluate all artificial neural networks in the population. Once the solutions with the highest prediction accuracy (fitness score) are selected for crossover and reproduction, the new population is generated.
Step 4:
Step 3 is repeated for a number of generations predefined by the user. Migration of best solutions occurs between CPUs during evolution for specified intervals.
Step 5: A fitness score is recorded for the test dataset by testing the overall best solution from the final generation to the test dataset.
Step 6: Steps 2-5 are repeated for each set of training and testing data.
The area under the curve of the receiver operating characteristic (AUC) was used in GENN as a fitness function.
Experiment setup
First, feature screening based on logistic regression was performed for each genomic dataset, since GENN has shown better performance compared to other methods when noise is reduced. 30 Since it is difficult to adjust potential confounding factors while learning predictive models, we used logistic regression to adjust them while screening significant genomic features associated with outcomes as a feature screening step. Then, each genomic dataset with a reduced number of features was used to learn GENN models using 5-fold cross-validation (CV). Second, in order to compare the models based on single genomic data and knowledge-driven data, each genomic dataset after feature screening was transformed into a knowledgedriven dataset based on pathway knowledge. To compare 2 models fairly, feature screening was also conducted for each knowledgedriven dataset. After the feature screening step, we used GENN to identify knowledge-driven genomic interaction models. Third, we integrated multiple knowledge-driven data to determine MKGIs associated with clinical outcomes of interest. All learning steps were repeated 5 times in order to assess the significance between performances, which resulted in 25 models (5CV * 5 times). Thus, an average AUC among 25 models was used as a performance measure to compare different models generated from either single genomic data or knowledge-driven data. GENN was run with 20 demes, 1000 population size/deme, 1000 generations, and migration every 20 generations as parameter setting to determine GENN models for each dataset.
RESULTS AND DISCUSSION
GENN modeling for identifying knowledge-driven genomic interactions
For the feature screening step, which used logistic regression, we used P ¼ 0.05 for CNA data and P ¼ 0.01 for methylation and gene expression data as thresholds, in order to have a similar number of screened features, which resulted in 87 CNA, 104 gene expression, and 70 methylation features for stage outcome. The feature screening step, with a similar set of thresholds, was performed for grade and survival outcomes. After feature screening, we ran GENN for each genomic dataset with screened features to obtain models based on genomic data alone. Then, the knowledge-driven data features after screening were used to determine knowledge-driven genomic interaction models. First, we compared the performance on models based on a single genomic data type with models based on knowledge-driven data (Table 4) . Overall, knowledge-driven genomic interaction models showed better performance than models based on a single genomic data type, except for methylation data. This suggests that incorporating biological knowledge into genomic data by building predefined features could result in better elucidation of clinical outcomes. Next, we compared the performance of knowledge-driven genomic interaction models generated from CNA, methylation, and gene expression datasets. Interestingly, such models based on gene expression profiles for the 3 outcomes outperformed those based on CNA and methylation data (Table 4 ). This suggests that gene expression may play a more important role in pathway levels than CNA and methylation in terms of prediction of clinical outcomes in cancer. In addition, to examine possible mechanisms of the knowledge-driven genomic interaction models to explain clinical outcomes, frequently selected pathway features based on cross-validation consistency (CVC) 3 times among 5-fold CV were compared among genomic datasets. Notably, knowledgedriven genomic interaction models from different genomic data shared few pathway features in predicting 3 clinical outcomes (Tables 5-7) . For a stage outcome, the salivary secretion pathway was shared by the knowledge-driven genomic interaction models generated from methylation and gene expression data only (Table 5) .
Integrating multiple knowledge-driven genomic interaction models
To determine MKGI models associated with clinical outcomes in ovarian cancer, multiple knowledge-driven datasets were integrated. Given the pathway features based on CVC 3 from each knowledge-driven genomic interaction model, the final metadimensional model was generated using GENN. Surprisingly, the integration models showed great improvement in terms of accuracy of predicting clinical outcomes when we combined knowledge-driven datasets based on CNA, methylation, and gene expression data (Table 4) . A Wilcoxon signed-rank test was performed to assess the significance between knowledge-driven dataset models and integration models. For 3 outcomes, integration model performance is significantly greater than that of the knowledge-driven genomic interaction models (Table 5 ). Figure 3 shows one of the best integration models, with many frequently selected pathway features among 5-fold CV intervals showing high performance. The final MKGI models contained pathway features from all 3 knowledge-driven datasets. For example, the metadimensional model for the survival outcome contains several features, including viral carcinogenesis and ubiquitin-mediated proteolysis from the CNA data, GnRH signaling pathway from the methylation data, and MAPK signaling pathway, protein digestion and absorption, other types of O-glycan biosynthesis, and Parkinson's disease from the gene expression dataset ( Figure 3C ). 
Biological implication
Our results suggest possible biological and clinical implications for ovarian cancer. Many cancer-related pathways have been found from the knowledge-driven genomic interaction models (Tables 5-7) . For example, the WNT signaling pathway and NOTCH signaling pathway were selected from knowledge-driven models based on CNA and gene expression data, respectively, for the stage outcome. The WNT signaling pathway is associated with cancers, including ovarian cancer, 31 and the NOTCH signaling pathway is known to be active in ovarian cancer and involved in ovarian cancer pathophysiology. 32, 33 For the grade outcome, the knowledge-driven interaction model based on CNA data contained the TGF-beta signaling pathway, which plays an important role in tumor suppression and cancer progression. 34 In addition, several cancer-related pathways, including the PI3K-Akt, GnRH, and MAPK signaling pathways, were selected from the models for the survival outcome. Notably, selected pathway features are not likely to be shared between knowledge-driven genomic interaction models based on different genomic datasets (Tables 5-7) . Moreover, performance significantly increased when multiple knowledge-driven datasets were integrated (Table 4) , and MKGI models show nonlinear interactions between selected pathway features ( Figure 3) . Generally, predicting stage and grade would be less useful than predicting survival in cancer. However, these molecular signatures based on genomic interactions could be used to help refine those ratings, in particular when they are borderline between categories. Taken together, these results suggest that selected pathways from different dimensional genomic data can somehow cooperate rather than act in isolation.
To examine the interplay between selected pathway features, we created a network using cBio portal. The network integrates biological interactions from publicly available databases, including NCINature Pathway Interaction Database, Reactome, HPRD, Pathway Commons, and MSKCC Cancer Call Map 21 ( Figure 4 ). Figure 4 shows an integrated network of genes that are in pathways found to be associated with survival outcome from integration results. The gene clusters are organized in a hierarchical manner, with genes from a single pathway in the top row, genes from 2 pathways in the second row, and so on. We found that the 2 sharing the most genes are the MAPK and GnRH signaling pathways, both of which are known to play important roles in cancer pathogenesis. A previous study found that GnRH, a regulator of the reproductive system, is responsible for the activation of MAPK cascades. 35 More specifically, p38 MAP, which is activated by GnRH-II, is known to be important in cell proliferation, differentiation, and apoptosis, while GnRH-II appears to have an antiproliferative effect in ovarian can- Figure 3 . Metadimensional knowledge-driven genomic interaction models for stage, grade, and survival outcomes. Multiple knowledge-driven datasets were combined to determine metadimensional models. CNA, Meth, and Gene represent pathway features from knowledge-driven data based on copy number alteration (CNA), methylation, and gene expression, respectively. Constants in the box are weights. PADD, PSUB, PMUL, and PDIV are addition, subtraction, multiplication, and division activation nodes, respectively. cer cells; thus, it is suggested that together they mediate cellular responses in those cells. 36 Additionally, it has been shown that GnRH could have potential benefits for ovarian cancer patients who do not respond to chemotherapy, 37 also demonstrated here by the large number of US Food and Drug Administration-approved drugs that target genes from both GnRH and MAPK signaling pathways, shown in Figure 4 . Another interesting connection is the possible interaction between the MAPK signaling pathway and Parkinson's disease. Results from 1 study suggested that activation of the MAPK p38, a known tumor suppressor, to inhibit tumor growth and metastasis in cancer patients could put them at risk of developing neurodegenerative disease, since activation of p38 is also associated with neurodegenerative diseases such as Parkinson's. 38 In another study, results showed that obstruction of lipogenic enzyme fatty acid synthase stimulates degradation of MAPK signaling proteins in ovarian carcinoma cells. They suggested that the degradation was caused in part by ubiquitination of the effector proteins. 39 Combined, these results show obvious links between pathways associated with ovarian cancer prognosis and the potential to develop therapies targeting those genes that connect the pathways (Figure 4) .
CONCLUSIONS
In the present study, we propose a new framework that incorporates biological knowledge into multi-omics data to identify MKGI associated with clinical outcomes in cancer. In an early stage of investigation, we posed the following questions: (1) Do knowledge-driven genomic interaction models using different multi-omics data contain similar or different sets of pathways? (2) Do MKGI models improve the ability to explain outcomes of interest as cross-talk between pathways altered by multi-omics data? For the first question, we found that each knowledge-driven genomic interaction model contains a different set of pathway features, suggesting that genomic data may contribute to outcomes in ovarian cancer via different pathways. To answer the latter question, we also found that MKGI models significantly outperformed the single knowledge-driven genomic interaction model. Since dimensional genomic data seem to contribute to cancer via different pathways, sets of pathways may synergistically interact and improve the accuracy of elucidating clinical outcomes when integrating multiple knowledge-driven genomic interaction models. Thus, it is important to integrate multi-omics data and incorporate biological knowledge into the model to examine interplays between different dimensional genomic data that are associated with clinical outcomes of interest in cancer.
The proposed framework has several advantages. As a concatenation-based integration approach, the model can capture combinations/interactions between genomic features extracted from different dimensional genomic data. 4 Since many MKGI models showed nonlinear interactions associated with each outcome (Figure  3 ), the effect would be missed if multiple knowledge-driven datasets were not combined into 1 model. In contrast to other gene-set approaches, such as gene set enrichment analysis, that focus on measuring enrichment of only 1 pathway at a time, 40 the proposed framework focuses on identifying combinations/interactions between pathways, such as cross-talk, based on genomic profiles associated with outcomes. In addition, the output model incorporating biological knowledge is more interpretable than the model based on the genomic dataset alone, since it is framed in the context of specific pathways. Future explorations of the present study include performing relevant simulation studies. Unfortunately, there is a lack of simulation tools to generate such biological knowledge affected by multi-omics data. Furthermore, it is difficult to simulate interactions between pathways altered by multi-omics data. Thus, one possible solution is to take the natural data and introduce real signals in silico. The dataset preserves the biological complexity, but there are some actual signals to detect. In addition, a supervised feature selection method could cause data-specific biases compared to the unsupervised method. In our study, however, logistic regression was used to reduce noise features as a screening step, and then an optimal set of features associated with outcomes was selected using GENN. Nevertheless, it would be important to look at the metadimensional models identified in the TCGA ovarian cancer data to see if the same or similar pathways are predictive of clinical outcomes in a completely independent dataset. Applying the proposed framework to other biological knowledge such as gene ontology or protein families would be a future direction, since Biofilter uses the built-in database LOKI, which contains multiple biological knowledge bases. The proposed framework could also be extended to integrate other omic data, such as somatic mutation or miRNA profiles. As a proof-of-concept study, we used an ovarian cancer dataset from TCGA; however, further exploration for other cancer types is warranted for such a pancancer analysis. 41 In particular, the level of noise in the genomic data might vary among different cancer types. For example, TCGA ovarian cancers uniquely have a higher level of noise in DNA copy number alterations than other TCGA cancer types. 41 Therefore, an appropriate feature screening step would be needed prior to identifying knowledge-driven genomic interactions. As demonstrated by this study, the beauty of incorporating biological knowledge into a model based on multi-omics data is the ability to improve diagnosis and prognosis and provide better interpretability. These metadimensional models that capture interactions between different pathways can better elucidate tumor heterogeneity. Thus, the variability in patients' molecular signatures based on these interactions between pathways may lead to better diagnostic/ treatment strategies for better precision medicine.
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